Kidney drug interaction study scrapped before it started
NCT ID NCT07515339
First seen Apr 12, 2026 · Last updated May 19, 2026 · Updated 5 times
Summary
This study was designed to see how a new experimental drug for chronic kidney disease, called nurandociguat, affects the way the body processes two common medicines (rosuvastatin and dabigatran) in healthy adults. The goal was to gather safety and drug-interaction information for future studies. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit
Mannheim, Baden-Wurttemberg, 68167, Germany
Conditions
Explore the condition pages connected to this study.